Sarecycline, sold under the brand name Seysara, is a narrow-spectrum tetracycline-derived antibiotic medication.

[2][3] It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

[1] Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest).

[1] Unlike other tetracycline-class antibiotics, sarecycline has a long C7 moiety that extends into and directly interact with the bacterial messenger RNA (mRNA).

[6] Sarecycline, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.